BMS’ LAG-3 RELATIVITY theory fails futility test
Source: Pharma Phorum, February 2024
Bristol-Myers Squibb has abandoned a bid to extend the indications of its combination of PD-1 inhibitor Opdivo and LAG-3 inhibitor relatlimab into colorectal cancer after it failed the phase 3 RELATIVITY-123 trial.
The trial of the fixed-dose combination of the two drugs – already approved as Opdualag (nivolumab and relatlimab) for skin cancer melanoma – has been abandoned after an interim analysis suggested it would be unlikely to show a positive result.
RELATIVITY-123 recruited 700 patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) whose disease has progressed following at least one, but no more than four, prior lines of therapy.